key: cord-0833093-mtyikuw0 authors: Tequare, Mengistu Hagazi; Abraha, Hiluf Ebuy; Adhana, Mache Tsadik; Tekle, Tesfay Hailu; Kebede Belayneh, Eskedar; Berhanu Gebresilassie, Kibrom; Wolderufael, Abadi Leul; Mohamedniguss Ebrahim, Mohamedawel; Afera Tadele, Berihun; Fikadu Berhe, Derbew; Mitiku Ashebir, Mengistu; Gebresilasie Gebrehiwot, Kibrom; Atsbaha, Merhawit; Alem Berihu, Birhane; Gebresilasie Desta, Kibrom; Atsbaha, Mussie Tesfay; Esayas Mengesha, Reiye; Tsegay, Mehari Abraha; Sibhatu, Manuel Kassaye title: Adverse Events of Oxford/AstraZeneca's COVID-19 Vaccine Among Health Workers of Ayder Comprehensive Specialized Hospital, Tigray, Ethiopia date: 2021-11-02 journal: nan DOI: 10.1016/j.ijregi.2021.10.013 sha: 16e52e7d79d17a51fcfa3b2cc6a3e6e13ec38fba doc_id: 833093 cord_uid: mtyikuw0 Background The safety of COVID vaccines should be continuously followed and this study reports Adverse Events of one of the COVID-19 vaccines. Methods A prospective single-cohort study design was conducted to assess Adverse Events Following Immunization (AEFI) and associated factors of first dose of Oxford/AstraZeneca's COVID-19 vaccine in Ayder Comprehensive specialized hospital (ACSH). A structured questionnaire was administered consecutively to 423 participants. Follow-up data were collected 72 hours after vaccination via phone. Bivariate and multivariate logistic regression models were used to see an association between adverse events and independent variables. Statistical significance declared at p < 0.05. Results Out of 423 health professionals who were approached, 395 responded. At least one adverse event (95% CI: 63.58, 72.77) was reported by 270 of them. Local and systemic symptoms occurred in 46.8% (95% CI: 41.94, 51.79) and 58.48% (95% CI: 53.53, 63.26)], respectively. Muscle ache, fatigue, headache, and fever were the commonest local symptoms. No reports of hospitalization, disability or death. Age (AOR=0.97, p=0.048), female sex (AOR=1.84, p=0.028), and comorbidity (AOR=2.28, p=0.040) were independent predictors of adverse events. Conclusion and recommendation AEFIs are commonly reported after first dose of COVID-19 vaccine; and age, female sex and comorbidity are independent predictors. Since its emergence, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has disrupted the global health and health systems, economies, and interactions (Paul & Divyanshi, 2021) . Up to 22 June 2021 it has infected around 180 million and claimed about 3.8 million lives worldwide (Worldometer, 2021) . In response to this catastrophe, hundreds of candidate vaccines have been on trial, of which some passed the acceptable efficacy and safety standards and have been deployed for use (Kirby, 2020; Onyeaka et al., 2021) . University of Oxford's and AstraZeneca's recombinant Chimpanzee vaccine is one among others (Onyeaka et al., 2021) . ChAdOx1 nCoV-19 is given by intramuscular injection, using as a vector the modified chimpanzee adenovirus -ChAdOx1 . Vaccine efficacy is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose and 81.3% after the second dose Voysey, Costa Clemens, et al., 2021) . On 30 December 2020, the vaccine was first approved for temporary use in the United Kingdom vaccination program (Gallagher & Triggle, 2020) and later by The World Health Organization (WHO) for emergency use (WHO, 2021a) . Following its use, various safety related-studies have started to emerge. They revealed that the vaccine has a good safety profile with some short-lived and self-limiting side effects, including injection-site pain, headache, nausea, vomiting, diarrhea, swelling, redness at the injection site, enlarged lymph nodes, decreased appetite, dizziness, sleepiness, sweating, abdominal pain, and so on. Rarely, however, some serious adverse effects, such as blood clots and anaphylaxis, have occurred (DIMITROVA, 2021). The vaccine is new and its safety has not been established in various geographic, demographic and ethnic populations. In other words, post-market adverse events should be studied and evidence should be generated sufficiently. Therefore, we aimed to determine occurrence of adverse events following the first dose of ChAdOx1 nCoV-19 vaccine among health workers at Ayder Comprehensive Specialized Hospital (ACSH). The study was conducted at ACSH from April 19, 2021 to May 3, 2021. ACSH is a tertiary care hospital located in Mekelle, Tigray, Northern Ethiopia. It provides a comprehensive set of specialized and general healthcare services. In addition, it serves as a teaching and research hospital under Mekelle University. It has around 1912 health professionals, practitioners, and academics comprising care. We employed a prospective single cohort study design among health professionals (practitioners, student-practitioners and academics) working in ACSH and were given the first dose of the ChAdOx1 nCoV-19 vaccine. All participants received 1 st dose of COVISHIELD, Oxford-AstraZeneca's COVID-19 vaccine which is produced by the Serum Institute of India (SII). The study was designed at two time periods. During their initial visit, all information on sociodemographic data and co-morbidity were collected. New symptoms which happened in the 72-hour post vaccine period, with their timing, were collected via telephone-based interviews (Figure 1 ). The sample size was calculated based on the formula for a single population proportion, where Zα/2 = 1.96, margin of error = 0.05, p = proportion of healthcare professionals with AEFI = 0.50 and q= 1-p: Sample size (n)= ( /2 ) 2 * * ( ) 2 = 384, adding 10% non-response rate, the minimum sample size was found to be 423. We used a consecutive sampling technique to collect data from the vaccination site. We found this site the most appropriate to get the study participants as they came for vaccination. Then we collected data consecutively until a sufficient sample was reached. Adverse events -A health problem that happens after vaccination may or may not be caused by a vaccine. Comorbidity -Chronic illnesses like diabetes, asthma, hypertension, renal disease, liver disease, cancer and so on Local symptoms -Symptoms occurring at or near the site of vaccine injection Systemic symptoms -Symptoms occurring at a point more or less remote from the injection arm The data collection tool was prepared through expert consultation and review of literature. Then the data were collected in two steps. Initially (T 0 ), we approached the health professionals to collect sociodemographic and morbidity data when they received their vaccine at the service area using face-to-face interviews. Their telephone number was taken and they were informed about a call after 72 hours. They were told to note and record any adverse effects following the vaccine. Later, after 72 hours (T 1 ), data about adverse effects and related timing was collected via phone call interview. This study adopted 72 hours because most adverse events occur within this period, as evidenced by recent studies (Menni et al., 2021; Shrestha et al., 2021)(12,13) The data collectors were well oriented on the importance of the study and were from the vaccination area. In addition, continuous supervision was made to ensure the quality of data. Furthermore, we then entered the data into EpiData, which minimizes data entry errors. The collected data were coded and entered into EpiData version 4.6. Then, exported into and analyzed using Stata version 15.0. Categorical variables were described using frequencies with percentages. Continuous variables were described using an appropriate combination of measure of central tendency and measure of dispersion. Proportions of occurrence of commonly reported adverse events were presented using a bar graph with its error bars. A binary logistic regression model was fitted to see if there was an association between adverse events and the independent variables. We exported independent variables with p < 0.25 in the bivariate analysis to multivariable logistic regression models. Statistical significance was declared at p < 0.05. Multicollinearity assumption and goodness of fit of the final model were checked using the Variance Inflation Factor (VIF) and Hosmer-Lemeshow test, respectively. During the study period, 423 study participants who received the COVID-19 vaccine were selected consecutively. Of these, 395 (93.38%) participants responded to the follow-up questionnaire through their phones. The median age of the subjects was 32 (IQR=15). The majority (69.37%) of the study participants were males. Regarding religion, 355 (89.87%) were Orthodox Christianity followers. More than half (53.67%) of the participants were married. Of the total participants who were approached, 43 (10.89%) had at least one comorbidity. Diabetic mellitus was the leading comorbidity (34.88%) reported, followed by hypertension (23.26%), and asthma (23.26%). Fourteen (3.54%) of the study participants had a known history of allergy to medications. Very few (1.77%) patients were positive for Covid-19 previously ( Table 1) . Other symptoms which were also reported by respondents include: rash 2 (0.50%), nasal bleeding 1 (0.25%), and dyspnea 1 (0.25%). Among 134 who responded, 46 (34.34%) reported they took medication by themselves ( Table 2) . Among the ten most commonly reported adverse events, the vast majority (81.19%) occurred within the first 24 hours of which nearly half (49.37%) of the events happened between 12 to 24 hours of post vaccination period. As shown in figure 2 , the proportion of adverse effect occurrence decreased tremendously from the first day (81.19%) to the second (16.11%) and the third day (2.70%). The majority of the specific AEFIs occurred from 12 to 24, hours followed by 6 to 12 hours after vaccination. A considerable proportion of nausea, stiffness of the arm on which the vaccine was injected, and injection site pain occurred in the first six hours. The nausea did not happen after 24 hours, while the weakness of the arm and swelling on the injection site happened after six hours (Figure 3 ) All the three explanatory variables (age, sex, and comorbidity) included in the final model were statistically significant predictors of AEFI. Accordingly, as age increases by one year, the odds of experiencing adverse events decrease by 3.0% (AOR=0.97, p=0.003) after adjusting for sex and comorbidity. In addition, the likelihood of side effect experience was higher among females than males (AOR=1.84, p=0.028) by adjusting it to age and comorbidity. Participants with comorbidity experienced more post vaccine symptoms (AOR=2.28, p=0.040) than with those without comorbidity (Table 3) , after adjusting to age and sex. The aim of the study was to determine the magnitude of adverse events and associated factors following ChAdOx1 nCoV-19 vaccine immunization among health workers. Of the total study participants, more than two-third experienced at least one adverse event. Majority of the adverse events happened within 24 hours after vaccination, showing sharp decline afterwards. Younger age, being female, and having comorbidity were independent predictors for AEFI incidence. The magnitude of occurrence of at least one adverse event varied in different studies. Studies from India (57% and 69.7%) (Kamal et al., 2021; Inbaraj et al., 2021) , and Togo (71.6%) (Konu et al., 2021) have reported findings consistent with this study (68.58%), while the number is much higher (90%) in Korean studies (Jeon et al., 2021; Bae et al., 2021) . It might have occurred because of ethnic differences. Evidence reports that ethnic differences may predict vulnerability for adverse drug reactions, in general (Baehr et al., 2015) . Report of systemic reaction following ChAdOx1 nCoV-19 in a randomized controlled trial was as high as 86% (Ramasamy et al., 2020) . However, the findings in this study (58.48%) are much lower. Another large-scale community-based study in the United Kingdom reported an even much lower rate of 33.7% (Menni et al., 2021) . The variation may be due to the difference in study designs and the heterogeneity of the populations. Most AEFIs revealed in this study are, at a less or greater rate, in line with any vaccine symptoms, including different COVID -19 vaccines and, specifically ChAdOx1 nCoV-19 (WHO, 2021b). They are short-lived, self-limiting symptoms and are mild and moderate in severity. In our study, from those who have reported, more than half of the participants said that they spontaneously cured and the rest took over-the-counter drugs. There was no report of serious adverse events, such as hospitalization, disability, and death. This is similar to results from other studies (Menni et al., 2021; Ramasamy et al., 2020) . In terms of occurrence over time, most AEFI happened within 24 hours following immunization. There was a sharp decline in the incidence of adverse events between 24 and 72 hours following vaccination. This corroborates other findings elsewhere Inbaraj et al., 2021) . Age, sex and comorbidity were associated with high incidence rate of AEFIs. Our findings show that younger study participants had more frequent symptoms, consistent with other findings (Menni et al., 2021; Kamal et al., 2021) . It may be due to higher reactogenicity among young people than their older counterparts (Ramasamy et al., 2020) . The probability of developing adverse effects following ChAdOx1 vaccine administration in females in our study is significantly higher (1.84 times) than that of males. This aligns with reports from different studies on this same vaccine (Gee, 2021; Blumenthal et al., 2021) . In general, evidence shows that females encounter an increased risk of vaccine-related adverse events than males (Klein & Flanagan, 2016) . This could be due to estrogen hormone, which triggers a robust immune response. Our study found more pronounced AEFIs occurred in participants with comorbidity than those without. On the contrary, two other studies from India (Kamal et al., 2021; Inbaraj et al., 2021) found no significant association between these two attributes. The difference might be due to the difference in methods and sample size. Our findings may have a positive policy and practice implications. It can also provide data on local vaccine related adverse effects for health professionals and the public. Our study has limitations and we advise a cautious consumption of the findings. The first limitation is that we used only health professionals, making it difficult to extrapolate the results to the broader human population. The short follow-up time (only 72 hours after vaccination) could be considered as the second limitation and leaves adverse events occurring after 72 hours untraced. Additional studies should be conducted to fix the limitations of our study and we advise researchers to conduct research with more frequent data collection, including immediate follow-up after vaccination and also trace adverse events happening after 72 hours. Furthermore, studies that include the wider population are highly recommended. AEFI of COVID vaccine is common among health professionals working in ACSH, Tigray. Nearly half and more than half of the study participants had at least one local and systemic symptom, respectively. Younger age, female, and having comorbidities were independent predictors for AEFI incidence. The authors declare no conflict of interest. This project was funded by Mekelle University. Ethical clearance was received from Mekelle University College of health sciences institutional review board. We also received written informed consent from each study participant. In addition, secured handling of the collected data was ensured. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea Racial and Ethnic Disparities in Adverse Drug Events: A Systematic Review of the Literature Acute Allergic Reactions to mRNA COVID-19 Vaccines Vaxzevria (previously COVID-19 Vaccine AstraZeneca) Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomized controlled trial Covid-19: Oxford-AstraZeneca vaccine approved for use in UK. BBC News First Month of COVID-19 Vaccine Safety Monitoring-United States How safe is Covishield (ChAdOx1nCoV-19) vaccine? Experience from a tertiary care hospital in South India Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System Adverse events following ChAdOx1 nCoV-19 Vaccine (COVISHIELD) amongst health care workers: A prospective observational study Development of potential COVID-19 vaccines continues to accelerate Sex differences in immune responses Prevalence of severe adverse events in health professionals after receiving the first dose of the COVID-19 vaccination in Togo Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study. The Lancet Infectious Diseases A review on the advancements in the development of vaccines to combat coronavirus disease 2019 2020 Year in Review: The impact of COVID-19 in 12 charts Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomized Adverse events following the first dose of ChAdOx1 nCoV-19 (COVISHIELD) vaccine in the first phase of vaccine roll out in Nepal Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. The Lancet Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomized trials Background document on the AZD1222 vaccine against COVID-19 developed by Oxford University and AstraZeneca. World Health Organisation COVID Live Update: 211,002,568 Cases and 4,419,834 Deaths from the Coronavirus-Worldometer The authors would like to thank the study participants.